Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHeather YoungbergMLMinetta C. LiuMNMayur Narkhede

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows ctDNA dynamics predict outcomes in DLBCL patients, suggesting earlier CAR-T referral may benefit high-risk individuals.

Key Points

  • The study aims to evaluate the effectiveness of WGS-based ctDNA monitoring in DLBCL patients and its association with treatment outcomes.
  • Retrospective analysis of ctDNA data from 49 patients with DLBCL
  • Plasma samples collected at various treatment stages
  • Used Signatera™ Genome for ctDNA detection
  • Evaluated ctDNA dynamics in relation to event-free survival using Cox regression analysis
  • 100% ctDNA-positivity rate pre-treatment
  • 19 patients achieved ctDNA clearance during therapy
  • CtDNA clearance correlated with superior event-free survival
  • PPV and NPV for a single ctDNA time point post CAR-T infusion were 100% for predicting long-term outcomes
  • Patients with early clearance showed the best outcomes, while those with late clearance had inferior results.

Cite This Study

Youngberg et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e111https://doi.org/10.1182/blood-2025-4353
View Full Paper
Ask AI
Bookmark
Share